{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:15:30Z","timestamp":1679231730135},"reference-count":10,"publisher":"Becaris Publishing Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            We examined characteristics of early sacubitril\/valsartan users in a large US electronic health records database.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            We identified three cohorts of patients with heart failure (HF): sacubitril\/valsartan patients with a prior HF diagnosis; patients with HF with reduced ejection fraction; and patients with HF treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a \u03b2-blocker.\n            <jats:bold>Results:<\/jats:bold>\n            Sacubitril\/valsartan patients were younger than patients in the other cohorts; the mean age of sacubitril\/valsartan patients increased by 2 years in the first 15 months of marketing. Most sacubitril\/valsartan patients had prior use of HF treatment.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Overall, sacubitril\/valsartan patients resembled those in the HF with reduced ejection fraction cohort, and commonly used other drugs for HF.\n          <\/jats:p>","DOI":"10.2217\/cer-2017-0088","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T10:41:39Z","timestamp":1535539299000},"page":"1073-1082","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics of early sacubitril\/valsartan patients and considerations for studies in electronic health record data"],"prefix":"10.57264","volume":"7","author":[{"given":"Joshua J","family":"Gagne","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Tsacogianis","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bruce Wirta","sequence":"additional","affiliation":[{"name":"Novartis Sverige AB, T\u00e4by 183 79, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R","family":"Rogers","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederico","family":"Calado","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel 4056, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Lan","family":"Chang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J","family":"Turner","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond G","family":"Schlienger","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel 4056, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Balas","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel 4056, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurrahman","family":"Abdurrob","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Najafzadeh","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley V","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"11","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJV","year":"2014","unstructured":"McMurray JJV , Packer M , Desai AS PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure . N. Engl. J. Med. 371 ( 11 ), 993 \u2013 1004 ( 2014 ).","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"e_1_3_4_4_2","first-page":"e298","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"134","author":"Yancy CW","year":"2016","unstructured":"Yancy CW , Jessup M , Bozkurt 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America . Circulation 134 ( 13 ), e298 ( 2016 ).","journal-title":"Circulation"},{"issue":"6","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/clpt.2011.235","article-title":"Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development","volume":"90","author":"Schneeweiss S","year":"2011","unstructured":"Schneeweiss S , Gagne JJ , Glynn RJ , Ruhl M , Rassen JA . Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development . Clin. Pharmacol. Ther. 90 ( 6 ), 777 \u2013 790 ( 2011 ).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jval.2013.05.008","article-title":"Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research","volume":"16","author":"Gagne JJ","year":"2013","unstructured":"Gagne JJ , Bykov K , Willke RJ , Kahler KH , Subedi P , Schneeweiss S . Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research . Value Health 16 ( 6 ), 1054 \u2013 1062 ( 2013 ).","journal-title":"Value Health"},{"issue":"3","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/heartjnl-2016-309561","article-title":"Incidence and risk of heart failure in systemic lupus erythematosus","volume":"103","author":"Kim CH","year":"2017","unstructured":"Kim CH , Al-Kindi SG , Jandali B , Askari AD , Zacharias M , Oliveira GH . Incidence and risk of heart failure in systemic lupus erythematosus . Heart 103 ( 3 ), 227 \u2013 233 ( 2017 ).","journal-title":"Heart"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2016.05.027","article-title":"Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities","volume":"218","author":"Al-Kindi SG","year":"2016","unstructured":"Al-Kindi SG , ElAmm C , Ginwalla M Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities . Int. J. Cardiol. 218 , 43 \u2013 46 ( 2016 ).","journal-title":"Int. J. Cardiol."},{"issue":"10","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1007\/s10620-016-4204-4","article-title":"The 2010-2015 prevalence of eosinophilic esophagitis in the USA: a population-based study","volume":"61","author":"Mansoor E","year":"2016","unstructured":"Mansoor E , Cooper GS . The 2010-2015 prevalence of eosinophilic esophagitis in the USA: a population-based study . Dig. Dis. Sci. 61 ( 10 ), 2928 \u2013 2934 ( 2016 ).","journal-title":"Dig. Dis. Sci."},{"issue":"3","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.ajog.2016.05.003","article-title":"Does pregnancy increase the risk of abdominal hernia recurrence after prepregnancy surgical repair?","volume":"215","author":"Lappen JR","year":"2016","unstructured":"Lappen JR , Sheyn D , Hackney DN . Does pregnancy increase the risk of abdominal hernia recurrence after prepregnancy surgical repair? Am. J. Obstet. Gynecol. 215 ( 3 ), 390.e1 \u2013 5 ( 2016 ).","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","article-title":"Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines \u2013 Heart Failure (GWTG-HF)","volume":"5","author":"Luo N","year":"2017","unstructured":"Luo N , Fonarow GC , Lippmann SJ Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines \u2013 Heart Failure (GWTG-HF) . JACC Heart Fail. 5 ( 4 ), 305 \u2013 309 ( 2017 ).","journal-title":"JACC Heart Fail."},{"issue":"7","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2015.07.018","article-title":"Comparison of risk and re-hospitalization, all-cause mortality, and medical resource utilization in patients with heart failure and preserved versus reduced ejection fraction","volume":"116","author":"Nichols GA","year":"2015","unstructured":"Nichols GA , Reynolds K , Kimes TM , Rosales AG , Chan WW . Comparison of risk and re-hospitalization, all-cause mortality, and medical resource utilization in patients with heart failure and preserved versus reduced ejection fraction . Am. J. Cardiol. 116 ( 7 ), 1088 \u2013 1092 ( 2015 ).","journal-title":"Am. J. Cardiol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2017-0088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:28:48Z","timestamp":1679228928000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2017-0088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.2217\/cer-2017-0088"],"URL":"https:\/\/doi.org\/10.2217\/cer-2017-0088","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}